|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0024264,
umls-concept:C0027651,
umls-concept:C0035015,
umls-concept:C0042210,
umls-concept:C0056912,
umls-concept:C1420652,
umls-concept:C1522538,
umls-concept:C1522673,
umls-concept:C1548437,
umls-concept:C1882923,
umls-concept:C2350332
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-2-6
|
|
pubmed:abstractText |
Ideal vaccines should be stable, safe, molecularly defined, and out-of-shelf reagents efficient at triggering effector and memory Ag-specific T cell-based immune responses. Dendritic cell-derived exosomes could be considered as novel peptide-based vaccines because exosomes harbor a discrete set of proteins, bear functional MHC class I and II molecules that can be loaded with synthetic peptides of choice, and are stable reagents that were safely used in pioneering phase I studies. However, we showed in part I that exosomes are efficient to promote primary MHC class I-restricted effector CD8(+) T cell responses only when transferred onto mature DC in vivo. In this work, we bring evidence that among the clinically available reagents, Toll-like receptor 3 and 9 ligands are elective adjuvants capable of triggering efficient MHC-restricted CD8(+) T cell responses when combined to exosomes. Exosome immunogenicity across species allowed to verify the efficacy of good manufactory procedures-manufactured human exosomes admixed with CpG oligonucleotides in prophylactic and therapeutic settings of melanoma in HLA-A2 transgenic mice. CpG adjuvants appear to be ideal adjuvants for exosome-based cancer vaccines.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Adjuvants, Immunologic,
http://linkedlifedata.com/resource/pubmed/chemical/CPG-oligonucleotide,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/DNA-Binding Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/HLA-A2 Antigen,
http://linkedlifedata.com/resource/pubmed/chemical/Ligands,
http://linkedlifedata.com/resource/pubmed/chemical/Membrane Glycoproteins,
http://linkedlifedata.com/resource/pubmed/chemical/Neoplasm Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Oligodeoxyribonucleotides,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Double-Stranded,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Cell Surface,
http://linkedlifedata.com/resource/pubmed/chemical/SILV protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Si protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/TLR3 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/TLR9 protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Tlr9 protein, mouse,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptor 3,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptor 9,
http://linkedlifedata.com/resource/pubmed/chemical/Toll-Like Receptors,
http://linkedlifedata.com/resource/pubmed/chemical/Vaccines, Subunit,
http://linkedlifedata.com/resource/pubmed/chemical/gp100 Melanoma Antigen
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0022-1767
|
|
pubmed:author |
pubmed-author:AdamsMalcolmM,
pubmed-author:AdemaGosseG,
pubmed-author:AndréFabriceF,
pubmed-author:AngevinEricE,
pubmed-author:AubertNathalieN,
pubmed-author:BernardJackyJ,
pubmed-author:BonnaventurePierreP,
pubmed-author:CarpentierAntoine FAF,
pubmed-author:ChaputNathalieN,
pubmed-author:EscudierBernardB,
pubmed-author:FerrantiniMariaM,
pubmed-author:LemonnierFrançoisF,
pubmed-author:MeradMiriamM,
pubmed-author:NovaultSophieS,
pubmed-author:SchartzNöel E CNE,
pubmed-author:TaïebJulienJ,
pubmed-author:TurszThomasT,
pubmed-author:ZitvogelLaurenceL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
172
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2137-46
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:14764679-Adjuvants, Immunologic,
pubmed-meshheading:14764679-Animals,
pubmed-meshheading:14764679-Cancer Vaccines,
pubmed-meshheading:14764679-Cell-Free System,
pubmed-meshheading:14764679-CpG Islands,
pubmed-meshheading:14764679-DNA-Binding Proteins,
pubmed-meshheading:14764679-Endosomes,
pubmed-meshheading:14764679-Graft Rejection,
pubmed-meshheading:14764679-HLA-A2 Antigen,
pubmed-meshheading:14764679-Humans,
pubmed-meshheading:14764679-Interphase,
pubmed-meshheading:14764679-Ligands,
pubmed-meshheading:14764679-Melanoma, Experimental,
pubmed-meshheading:14764679-Membrane Glycoproteins,
pubmed-meshheading:14764679-Mice,
pubmed-meshheading:14764679-Neoplasm Proteins,
pubmed-meshheading:14764679-Oligodeoxyribonucleotides,
pubmed-meshheading:14764679-RNA, Double-Stranded,
pubmed-meshheading:14764679-Receptors, Cell Surface,
pubmed-meshheading:14764679-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:14764679-T-Lymphocytes, Regulatory,
pubmed-meshheading:14764679-Toll-Like Receptor 3,
pubmed-meshheading:14764679-Toll-Like Receptor 9,
pubmed-meshheading:14764679-Toll-Like Receptors,
pubmed-meshheading:14764679-Vaccines, Subunit,
pubmed-meshheading:14764679-gp100 Melanoma Antigen
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Exosomes as potent cell-free peptide-based vaccine. II. Exosomes in CpG adjuvants efficiently prime naive Tc1 lymphocytes leading to tumor rejection.
|
|
pubmed:affiliation |
Unité d'Immunologie, ERM0208 Institut National de la Santé et de la Recherche Médicale, Department of Clinical Biology, Institut Gustave Roussy, Villejuif, France.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
